Alan Meeker
Overview
Explore the profile of Alan Meeker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ayyappan V, Jenkinson N, Tressler C, Tan Z, Cheng M, Shen X, et al.
Cell Rep
. 2024 Apr;
43(4):114121.
PMID: 38615320
Metabolic reprogramming is a hallmark of cancer, enabling cancer cells to rapidly proliferate, invade, and metastasize. We show that creatine levels in metastatic breast cancer cell lines and secondary metastatic...
2.
Shmerling M, Chalik M, Smorodinsky N, Meeker A, Roy S, Sagi-Assif O, et al.
Immunohorizons
. 2022 Apr;
6(4):253-272.
PMID: 35440514
Syntenic genomic loci on human chromosome 8 and mouse chromosome 15 (mChr15) code for LY6/Ly6 (lymphocyte Ag 6) family proteins. The 23 murine family genes include eight genes that are...
3.
Li Q, Chen J, Hu Y, Hoti N, Lih T, Thomas S, et al.
Sci Rep
. 2021 Sep;
11(1):18936.
PMID: 34556748
Prostate cancer (PCa) is a heterogeneous group of tumors with variable clinical courses. In order to improve patient outcomes, it is critical to clinically separate aggressive PCa (AG) from non-aggressive...
4.
Zhan D, Ma D, Wei S, Lal B, Fu Y, Eberhart C, et al.
Mol Cancer Res
. 2021 Aug;
19(11):1878-1888.
PMID: 34348994
Heterozygous isocitrate dehydrogenase (IDH) R132H mutation (IDH1) is an early event during gliomagenesis. Clinically, patients with glioma carrying mutant IDH1 respond better to antitumor therapies. However, the mechanism by which...
5.
Pichinuk E, Chalik M, Benhar I, Ginat-Koton R, Ziv R, Smorodinsky N, et al.
Cancer Immunol Immunother
. 2020 Mar;
69(7):1337-1352.
PMID: 32219500
Cleavage of the MUC1 glycoprotein yields two subunits, an extracellular alpha-subunit bound to a smaller transmembrane beta-subunit. Monoclonal antibodies (mAbs) directed against the MUC1 alpha-beta junction comprising the SEA domain,...
6.
Gorbounov M, Carleton N, Asch-Kendrick R, Xian L, Rooper L, Chia L, et al.
Breast Cancer Res Treat
. 2019 Sep;
179(1):25-35.
PMID: 31531802
Purpose: The high mobility group A1 (HMGA1) chromatin remodeling protein is required for metastatic progression and cancer stem cell properties in preclinical breast cancer models, although its role in breast...
7.
Amano H, Chaudhury A, Rodriguez-Aguayo C, Lu L, Akhanov V, Catic A, et al.
Cell Metab
. 2019 Apr;
29(6):1274-1290.e9.
PMID: 30930169
Telomere shortening is associated with stem cell decline, fibrotic disorders, and premature aging through mechanisms that are incompletely understood. Here, we show that telomere shortening in livers of telomerase knockout...
8.
Nunez F, Mendez F, Kadiyala P, Alghamri M, Savelieff M, Garcia-Fabiani M, et al.
Sci Transl Med
. 2019 Feb;
11(479).
PMID: 30760578
Patients with glioma whose tumors carry a mutation in isocitrate dehydrogenase 1 (IDH1) are younger at diagnosis and live longer. mutations co-occur with other molecular lesions, such as 1p/19q codeletion,...
9.
Demicco E, Wani K, Ingram D, Wagner M, Maki R, Rizzo A, et al.
Histopathology
. 2018 Jul;
73(5):843-851.
PMID: 29985536
Aims: TERT promoter mutations have been reported in 22% of solitary fibrous tumours (SFT) and have been associated with poor outcomes. We performed testing for TERT hot-spot mutations in a...
10.
Thompson E, Taube J, Asch-Kendrick R, Ogurtsova A, Xu H, Sharma R, et al.
Mod Pathol
. 2017 Jul;
30(11):1551-1560.
PMID: 28731046
Tumor-infiltrating lymphocytes and immune checkpoint proteins such as PD-L1 are potential prognostic factors and therapeutic targets in breast cancer. Most studies characterizing the breast tumor immune microenvironment have focused on...